File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antifungal prophylaxis and treatment in patients with hematological malignancies

TitleAntifungal prophylaxis and treatment in patients with hematological malignancies
Authors
Issue Date2010
PublisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7
Citation
Expert Review Of Anti-Infective Therapy, 2010, v. 8 n. 4, p. 397-404 How to Cite?
AbstractInvasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment, antifungal prophylaxis and empirical antifungal therapy are standard management approaches. Novel agents, such as posaconazole and echinocandins, broaden our armamentarium against IFIs and improve patients outcomes. © 2010 Expert Reviews Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/124915
ISSN
2015 Impact Factor: 3.542
2015 SCImago Journal Rankings: 1.415
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHwang, YYen_HK
dc.contributor.authorLiang, Ren_HK
dc.date.accessioned2010-10-31T11:01:17Z-
dc.date.available2010-10-31T11:01:17Z-
dc.date.issued2010en_HK
dc.identifier.citationExpert Review Of Anti-Infective Therapy, 2010, v. 8 n. 4, p. 397-404en_HK
dc.identifier.issn1478-7210en_HK
dc.identifier.urihttp://hdl.handle.net/10722/124915-
dc.description.abstractInvasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment, antifungal prophylaxis and empirical antifungal therapy are standard management approaches. Novel agents, such as posaconazole and echinocandins, broaden our armamentarium against IFIs and improve patients outcomes. © 2010 Expert Reviews Ltd.en_HK
dc.languageengen_HK
dc.publisherExpert Reviews Ltd. The Journal's web site is located at http://www.future-drugs.com/publication.asp?publicationid=7en_HK
dc.relation.ispartofExpert Review of Anti-Infective Therapyen_HK
dc.subject.meshAntifungal Agents - therapeutic useen_HK
dc.subject.meshHematologic Neoplasms - complicationsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMycoses - prevention & controlen_HK
dc.subject.meshOpportunistic Infections - drug therapyen_HK
dc.titleAntifungal prophylaxis and treatment in patients with hematological malignanciesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1478-7210&volume=8&spage=397&epage=404&date=2010&atitle=Antifungal+prophylaxis+and+treatment+in+patients+with+hematological+malignanciesen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1586/eri.10.16en_HK
dc.identifier.pmid20377335-
dc.identifier.scopuseid_2-s2.0-77950798682en_HK
dc.identifier.hkuros180744en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77950798682&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume8en_HK
dc.identifier.issue4en_HK
dc.identifier.spage397en_HK
dc.identifier.epage404en_HK
dc.identifier.isiWOS:000277378500010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHwang, YY=18134023400en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.citeulike7014049-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats